7-hydroxy-2-n,n-dipropylaminotetralin has been researched along with Parkinson Disease, Secondary in 2 studies
7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ueda, H | 1 |
| Sato, K | 1 |
| Okumura, F | 1 |
| Misu, Y | 1 |
| Bordet, R | 1 |
| Ridray, S | 1 |
| Schwartz, JC | 1 |
| Sokoloff, P | 1 |
2 other studies available for 7-hydroxy-2-n,n-dipropylaminotetralin and Parkinson Disease, Secondary
| Article | Year |
|---|---|
L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats.
Topics: Acetylcholine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agon | 1995 |
Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzazepines; Binding, Competitive; Corpus Striatum; Denervation; Diz | 2000 |